Ownership and insider activity for Puma Biotechnology, Inc. (PBYI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
Price
| Price | $9.39 |
| Market Cap | $478M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-14 | WILSON TROY EDWARD | S-Sale | 5,000 | $46K |
| 2026-09-14 | Cesano Alessandra | M-Exempt | 50,000 | $146K |
| 2026-09-14 | Cesano Alessandra | S-Sale | 62,150 | $567K |
| 2026-09-14 | Cesano Alessandra | M-Exempt | 50,000 | $146K |
| 2026-07-06 | AUERBACH ALAN H | S-Sale | 44,058 | $364K |
| 2026-07-06 | HUNT DOUGLAS M | S-Sale | 8,460 | $70K |
| 2026-07-06 | NOUGUES MAXIMO F | S-Sale | 9,386 | $78K |
| 2026-06-11 | WILSON TROY EDWARD | A-Award | 27,000 | |
| 2026-06-12 | WILSON TROY EDWARD | S-Sale | 10,800 | $78K |
| 2026-06-11 | Stuglik Brian M | A-Award | 27,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $194.5M | $81.7M | $108.4M | $60.0M | $85.3M | $63.1M | $76.2M | $84.6M | $69.2M | $29.6M |
| Short-term Investments | 0 | 0 | 0 | $51.6M | $8.1M | $19.0M | $4.9M | $11.4M | $31.7M | $67.9M |
| Receivables | 0 | $9.7M | $21.9M | $28.9M | $25.5M | $32.5M | $42.3M | $48.5M | $32.0M | $53.7M |
| Inventory | 0 | $2.0M | $2.6M | $3.2M | $3.5M | $7.1M | $4.5M | $7.1M | $8.7M | $5.5M |
| Total Current Assets | $236.5M | $106.4M | $203.0M | $166.3M | $146.1M | $140.0M | $134.3M | $156.2M | $147.7M | $162.7M |
| Property, Plant & Equipment | $5.2M | $4.5M | $4.0M | $21.8M | $18.9M | $15.8M | $12.5M | $8.6M | $5.1M | $5.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $48.4M | $44.4M | $40.5M | $74.1M | $66.1M | $70.6M | $60.9M | $51.1M | $41.4M |
| Total Assets | $252.8M | $165.5M | $259.1M | $234.9M | $244.2M | $226.6M | $222.1M | $230.5M | $213.3M | $216.3M |
| Accounts Payable | $20.0M | $27.7M | $20.7M | $19.2M | $12.1M | $11.2M | $6.4M | $6.9M | $5.5M | $5.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | $14.3M | 0 | 0 | $34.0M | $45.3M | $22.5M |
| Total Current Liabilities | $37.5M | $58.3M | $67.1M | $90.8M | $114.3M | $109.6M | $77.5M | $99.4M | $96.1M | $81.3M |
| Long-term Debt | 0 | $48.5M | $151.9M | $95.0M | $84.0M | $97.1M | $98.3M | $65.7M | $21.7M | 0 |
| Total Liabilities | $43.0M | $112.2M | $224.8M | $217.4M | $250.2M | $229.0M | $200.5M | $177.1M | $121.2M | $86.0M |
| Retained Earnings | -$796.5M | -$1.09B | -$1.20B | -$1.28B | -$1.34B | -$1.37B | -$1.37B | -$1.35B | -$1.31B | -$1.28B |
| Total Equity | $209.8M | $53.3M | $34.3M | $17.5M | -$6.0M | -$2.4M | $21.6M | $53.4M | $92.1M | $130.3M |
| Total Debt | 0 | $48.5M | $151.9M | $120.2M | $121.0M | $116.6M | $114.3M | $111.5M | $74.1M | $28.5M |
| Net Debt | -$194.5M | -$33.2M | $43.5M | $8.6M | $27.6M | $34.5M | $33.2M | $15.6M | -$26.9M | -$69.0M |
| Working Capital | $199.0M | $48.1M | $135.9M | $75.5M | $31.9M | $30.4M | $56.8M | $56.8M | $51.5M | $81.4M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.91 |
| Piotroski F-Score | 7 |
| Altman Z-Score | -4.16 |
Profitability
| Return on Equity | 20.85% |
| Return on Invested Capital | 18.20% |
| Return on Assets | 13.86% |
| Gross Margin | 74.83% |
| Operating Margin | 13.16% |
| Net Margin | 11.55% |
Related companies: ABEO · ALLO · ARCT · AVIR · ELDN · HUMA · SGMT
Explore sector: Healthcare · Biotechnology
More sections of PBYI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks